Published in Neuroimage on July 06, 2012
Risky decision-making and ventral striatal dopamine responses to amphetamine: a positron emission tomography [(11)C]raclopride study in healthy adults. Neuroimage (2015) 1.48
Gambling disorder and other behavioral addictions: recognition and treatment. Harv Rev Psychiatry (2015) 1.03
Imaging addiction: D2 receptors and dopamine signaling in the striatum as biomarkers for impulsivity. Neuropharmacology (2013) 1.01
In vivo evidence for greater amphetamine-induced dopamine release in pathological gambling: a positron emission tomography study with [(11)C]-(+)-PHNO. Mol Psychiatry (2013) 1.00
Neurobiology of gambling behaviors. Curr Opin Neurobiol (2013) 0.97
Disordered gambling: the evolving concept of behavioral addiction. Ann N Y Acad Sci (2014) 0.97
The neural bases of cognitive processes in gambling disorder. Trends Cogn Sci (2014) 0.96
Reward, interrupted: Inhibitory control and its relevance to addictions. Neuropharmacology (2013) 0.94
The functional anatomy of impulse control disorders. Curr Neurol Neurosci Rep (2013) 0.94
Risk-taking and decision-making in youth: relationships to addiction vulnerability. J Behav Addict (2013) 0.88
Neurobiological underpinnings of reward anticipation and outcome evaluation in gambling disorder. Front Behav Neurosci (2014) 0.88
How central is dopamine to pathological gambling or gambling disorder? Front Behav Neurosci (2013) 0.87
Integrating affect and impulsivity: The role of positive and negative urgency in substance use risk. Drug Alcohol Depend (2016) 0.84
Pathological choice: the neuroscience of gambling and gambling addiction. J Neurosci (2013) 0.84
Getting a grip on problem gambling: what can neuroscience tell us? Front Behav Neurosci (2014) 0.83
The Iowa Gambling Task and the three fallacies of dopamine in gambling disorder. Front Psychol (2013) 0.82
Brain structure correlates of emotion-based rash impulsivity. Neuroimage (2015) 0.82
Commentary on: Are we overpathologizing everyday life? A tenable blueprint for behavioral addiction research. J Behav Addict (2015) 0.82
Dopaminergic function and intertemporal choice. Transl Psychiatry (2015) 0.81
Blunted Endogenous Opioid Release Following an Oral Amphetamine Challenge in Pathological Gamblers. Neuropsychopharmacology (2015) 0.80
Impulsivity in abstinent alcohol and polydrug dependence: a multidimensional approach. Psychopharmacology (Berl) (2016) 0.78
Commentary on Boileau et al. (2013): Distinguishing D2/D3 dopaminergic contributions to addictions. Addiction (2013) 0.78
Neuroimaging and biomarkers in addiction treatment. Curr Psychiatry Rep (2014) 0.77
Amplified Striatal Responses to Near-Miss Outcomes in Pathological Gamblers. Neuropsychopharmacology (2016) 0.77
Prediction of striatal D2 receptor binding by DRD2/ANKK1 TaqIA allele status. Synapse (2016) 0.77
Brain Imaging in Gambling Disorder. Curr Addict Rep (2015) 0.77
Abnormal modulation of reward versus punishment learning by a dopamine D2-receptor antagonist in pathological gamblers. Psychopharmacology (Berl) (2015) 0.76
Cognitive distortions and ADHD in pathological gambling: A national longitudinal case-control cohort study. J Behav Addict (2016) 0.75
Right inferior frontal cortex activity correlates with tolcapone responsivity in problem and pathological gamblers. Neuroimage Clin (2016) 0.75
A Preliminary Study of DBH (Encoding Dopamine Beta-Hydroxylase) Genetic Variation and Neural Correlates of Emotional and Motivational Processing in Individuals With and Without Pathological Gambling. J Behav Addict (2016) 0.75
Dopamine and Opioid Neurotransmission in Behavioral Addictions: A Comparative PET Study in Pathological Gambling and Binge Eating. Neuropsychopharmacology (2016) 0.75
Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol Dependence. Neuropsychopharmacology (2017) 0.75
The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry (1998) 65.11
Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A (1988) 11.96
Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab (2007) 11.79
The South Oaks Gambling Screen (SOGS): a new instrument for the identification of pathological gamblers. Am J Psychiatry (1987) 9.84
Brain dopamine and obesity. Lancet (2001) 8.00
Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science (2007) 6.75
Impulsivity as a vulnerability marker for substance-use disorders: review of findings from high-risk research, problem gamblers and genetic association studies. Neurosci Biobehav Rev (2008) 4.97
Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am J Psychiatry (2001) 4.37
Integration of impulsivity and positive mood to predict risky behavior: development and validation of a measure of positive urgency. Psychol Assess (2007) 4.22
Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biol Psychiatry (2011) 3.78
Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature (1997) 3.76
Emotion-based dispositions to rash action: positive and negative urgency. Psychol Bull (2008) 3.70
DSM-IV pathological gambling in the National Comorbidity Survey Replication. Psychol Med (2008) 3.44
A pathways model of problem and pathological gambling. Addiction (2002) 3.29
Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab (2003) 3.21
PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys. Nat Neurosci (2006) 3.13
Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat Neurosci (2005) 2.90
Correlation between dopamine D(2) receptors in the ventral striatum and central processing of alcohol cues and craving. Am J Psychiatry (2004) 2.84
Striatal dopamine d2/d3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity. J Neurosci (2009) 2.78
Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels. Am J Psychiatry (1999) 2.49
Dopaminergic network differences in human impulsivity. Science (2010) 2.49
Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain (2009) 2.35
Cocaine dependence and d2 receptor availability in the functional subdivisions of the striatum: relationship with cocaine-seeking behavior. Neuropsychopharmacology (2004) 2.24
Drug addiction endophenotypes: impulsive versus sensation-seeking personality traits. Biol Psychiatry (2010) 2.13
Age-related cognitive deficits mediated by changes in the striatal dopamine system. Am J Psychiatry (2000) 2.12
Development and psychometric evaluation of a three-dimensional Gambling Motives Questionnaire. Addiction (2008) 2.05
Similarities and differences between pathological gambling and substance use disorders: a focus on impulsivity and compulsivity. Psychopharmacology (Berl) (2011) 1.77
Dopamine transmission in the human striatum during monetary reward tasks. J Neurosci (2004) 1.63
Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol (2009) 1.61
Quantification of amphetamine-induced changes in [11C]raclopride binding with continuous infusion. J Cereb Blood Flow Metab (1997) 1.55
Association of low striatal dopamine d2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse. Am J Psychiatry (2008) 1.53
Lower level of endogenous dopamine in patients with cocaine dependence: findings from PET imaging of D(2)/D(3) receptors following acute dopamine depletion. Am J Psychiatry (2009) 1.53
Correction of head movement on PET studies: comparison of methods. J Nucl Med (2006) 1.50
Shared brain vulnerabilities open the way for nonsubstance addictions: carving addiction at a new joint? Ann N Y Acad Sci (2010) 1.46
Personality and problem gambling: a prospective study of a birth cohort of young adults. Arch Gen Psychiatry (2005) 1.45
Dorsolateral prefrontal γ-aminobutyric acid in men predicts individual differences in rash impulsivity. Biol Psychiatry (2011) 1.31
The dopaminergic basis of human behaviors: A review of molecular imaging studies. Neurosci Biobehav Rev (2009) 1.30
Comparison of the transient equilibrium and continuous infusion method for quantitative PET analysis of [11C]raclopride binding. J Cereb Blood Flow Metab (1998) 1.25
Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. Brain (2011) 1.22
Pathological gambling among adolescents: Massachusetts Gambling Screen (MAGS). J Gambl Stud (1994) 1.20
Measurement of dopamine release with continuous infusion of [11C]raclopride: optimization and signal-to-noise considerations. J Nucl Med (2000) 1.20
Altered dopamine function in pathological gambling. Psychol Med (1997) 1.16
Dopamine release in ventral striatum during Iowa Gambling Task performance is associated with increased excitement levels in pathological gambling. Addiction (2010) 1.14
Impulsivity and cognitive distortions in pathological gamblers attending the UK National Problem Gambling Clinic: a preliminary report. Psychol Med (2011) 1.12
Gambling severity predicts midbrain response to near-miss outcomes. J Neurosci (2010) 1.11
Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial. J Clin Psychiatry (2008) 1.11
Inverted-U-shaped correlation between dopamine receptor availability in striatum and sensation seeking. Proc Natl Acad Sci U S A (2010) 1.09
Neuroendocrine response to casino gambling in problem gamblers. Psychoneuroendocrinology (2004) 1.09
Mesolimbic dopamine release is linked to symptom severity in pathological gambling. Neuroimage (2012) 1.07
A double-blind, placebo-controlled trial of olanzapine for the treatment of video poker pathological gamblers. Pharmacol Biochem Behav (2008) 1.01
Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling. Neurobiol Dis (2010) 1.01
Significant decreases in frontal and temporal [11C]-raclopride binding after THC challenge. Neuroimage (2010) 0.94
Dopaminergic activity in depressed smokers: a positron emission tomography study. Synapse (2009) 0.94
Effects of age on dopamine D2 receptor availability in striatal subdivisions: a high-resolution positron emission tomography study. Eur Neuropsychopharmacol (2011) 0.93
Acute effect of the anti-addiction drug bupropion on extracellular dopamine concentrations in the human striatum: an [11C]raclopride PET study. Neuroimage (2009) 0.84
Pathological gambling: a neurobiological and clinical update. Br J Psychiatry (2011) 0.82
Pathological gambling and the treatment of psychosis with aripiprazole: case reports. Br J Psychiatry (2011) 0.80
Cortical GABAergic regulation of dopaminergic responses to psychological stress in the rat dorsolateral striatum. Synapse (2005) 0.78
Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol (2006) 2.56
Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study. Am J Psychiatry (2011) 2.37
Rates of problematic gambling in a British homeless sample: a preliminary study. J Gambl Stud (2015) 2.07
Microglial activation in presymptomatic Huntington's disease gene carriers. Brain (2007) 1.93
Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol (2005) 1.88
Uncritical positive regard? Issues in the efficacy and safety of psychotherapy. J Psychopharmacol (2008) 1.80
Role of GABA in anxiety and depression. Depress Anxiety (2007) 1.79
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A (2012) 1.79
Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci Transl Med (2010) 1.78
Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an in vivo 11C-raclopride PET study. Exp Neurol (2008) 1.77
Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci (2002) 1.74
Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. Biol Psychiatry (2010) 1.69
Priorities in Parkinson's disease research. Nat Rev Drug Discov (2011) 1.66
Increased PK11195 PET binding in the cortex of patients with MS correlates with disability. Neurology (2012) 1.63
The size, burden and cost of disorders of the brain in the UK. J Psychopharmacol (2013) 1.62
Acute tryptophan depletion. Part II: clinical effects and implications. Aust N Z J Psychiatry (2005) 1.62
GABA system dysfunction in autism and related disorders: from synapse to symptoms. Neurosci Biobehav Rev (2012) 1.61
Gene expression subtypes in patients with chronic fatigue syndrome/myalgic encephalomyelitis. J Infect Dis (2008) 1.59
Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. J Clin Invest (2014) 1.58
Increased dopamine tone during meditation-induced change of consciousness. Brain Res Cogn Brain Res (2002) 1.55
A tale of two Es. J Psychopharmacol (2006) 1.53
Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann Neurol (2002) 1.51
In vivo assessment of brain monoamine systems in parkin gene carriers: a PET study. Exp Neurol (2010) 1.47
Substitution therapy for alcoholism: time for a reappraisal? J Psychopharmacol (2011) 1.47
Cognitive deficits and striato-frontal dopamine release in Parkinson's disease. Brain (2008) 1.45
MDMA, politics and medical research: have we thrown the baby out with the bathwater? J Psychopharmacol (2007) 1.42
Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiol Dis (2010) 1.41
Parkinson's disease symptoms: the patient's perspective. Mov Disord (2010) 1.40
Dopamine and social anxiety disorder. Rev Bras Psiquiatr (2006) 1.38
Prescribing antidepressants post Cipriani et al. J Psychopharmacol (2009) 1.37
Human taste thresholds are modulated by serotonin and noradrenaline. J Neurosci (2006) 1.36
Psychotropic drugs, cardiac arrhythmia, and sudden death. J Clin Psychopharmacol (2003) 1.36
Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol (2014) 1.36
Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. Hum Brain Mapp (2011) 1.32
Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. Brain (2002) 1.30
Tryptophan metabolism in the central nervous system: medical implications. Expert Rev Mol Med (2006) 1.25
Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. Brain (2011) 1.22
Amphetamine, past and present--a pharmacological and clinical perspective. J Psychopharmacol (2013) 1.22
Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. J Psychopharmacol (2014) 1.22
Antidepressant-induced jitteriness/anxiety syndrome: systematic review. Br J Psychiatry (2009) 1.20
Measuring endogenous 5-HT release by emission tomography: promises and pitfalls. J Cereb Blood Flow Metab (2010) 1.16
Association of the anxiogenic and alerting effects of caffeine with ADORA2A and ADORA1 polymorphisms and habitual level of caffeine consumption. Neuropsychopharmacology (2010) 1.16
Hypothalamic involvement in Huntington's disease: an in vivo PET study. Brain (2008) 1.15
The effect of nicotine on striatal dopamine release in man: A [11C]raclopride PET study. Synapse (2007) 1.15
Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. Mov Disord (2011) 1.14
Correlation of subjective and objective sleep measurements at different stages of the treatment of depression. Psychiatry Res (2003) 1.13
Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain (2003) 1.13
Imaging microglial activation in Huntington's disease. Brain Res Bull (2006) 1.12
Functional connectivity analysis of the neural circuits of opiate craving: "more" rather than "different"? Neuroimage (2003) 1.10
5-HT radioligands for human brain imaging with PET and SPECT. Med Res Rev (2011) 1.10
Effects of acute tyrosine/phenylalanine depletion on the selective processing of smoking-related cues and the relative value of cigarettes in smokers. Psychopharmacology (Berl) (2007) 1.10
Cape Town consensus on posttraumatic stress disorder. CNS Spectr (2009) 1.09
Behavioral and cardiovascular effects of 7.5% CO2 in human volunteers. Depress Anxiety (2005) 1.09
Consensus statement update on posttraumatic stress disorder from the international consensus group on depression and anxiety. J Clin Psychiatry (2004) 1.08
Imaging in Parkinson's disease: the role of monoamines in behavior. Biol Psychiatry (2006) 1.08
Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry (2006) 1.08
Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol (2007) 1.07
Broadband cortical desynchronization underlies the human psychedelic state. J Neurosci (2013) 1.07
Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder. Curr Opin Pharmacol (2005) 1.07
WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr (2003) 1.06
Blockade of alcohol's amnestic activity in humans by an alpha5 subtype benzodiazepine receptor inverse agonist. Neuropharmacology (2007) 1.05
Harms associated with psychoactive substances: findings of the UK National Drug Survey. J Psychopharmacol (2009) 1.05
Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease. Brain (2013) 1.05
Serotonin 5-HT1A receptor binding in people with panic disorder: positron emission tomography study. Br J Psychiatry (2008) 1.04
Gamma hydroxy butyrate abuse and dependency. J Psychopharmacol (2005) 1.03
Transition to psychosis associated with prefrontal and subcortical dysfunction in ultra high-risk individuals. Schizophr Bull (2012) 1.03
Decision making, impulsivity, and addictions: do Parkinson's disease patients jump to conclusions? Mov Disord (2012) 1.03
Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis. Schizophr Bull (2012) 1.03
Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts. Sci Transl Med (2012) 1.02
Is there cognitive impairment in clinically 'healthy' abstinent alcohol dependence? Alcohol Alcohol (2005) 1.01
Anhedonia revisited: is there a role for dopamine-targeting drugs for depression? J Psychopharmacol (2013) 1.00
Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging study. Brain (2013) 1.00
GABAB receptors in addiction and its treatment. Adv Pharmacol (2010) 1.00
Association between the serotonin transporter gene and alcohol consumption in social drinkers. Am J Med Genet B Neuropsychiatr Genet (2005) 1.00
Orexin-A infusion in the locus ceruleus triggers norepinephrine (NE) release and NE-induced long-term potentiation in the dentate gyrus. J Neurosci (2004) 0.99
In vitro and ex vivo distribution of [3H]harmane, an endogenous beta-carboline, in rat brain. Neuropharmacology (2005) 0.99
Changes in cardiovascular function after venlafaxine but not pregabalin in healthy volunteers: a double-blind, placebo-controlled study of orthostatic challenge, blood pressure and heart rate. Hum Psychopharmacol (2013) 0.98
Preliminary evidence of anxiolytic effects of the CRF(1) receptor antagonist R317573 in the 7.5% CO(2) proof-of-concept experimental model of human anxiety. J Psychopharmacol (2011) 0.98
Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study. Brain (2003) 0.98
Endogenous opioid release in the human brain reward system induced by acute amphetamine administration. Biol Psychiatry (2012) 0.98
Classification of schizophrenic patients and healthy controls using [18F] fluorodopa PET imaging. Schizophr Res (2008) 0.98
The catechol-O-methyltransferase Val(158)Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson's disease: a PET study. Brain (2012) 0.97
Microbial infections in eight genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis. J Clin Pathol (2009) 0.97
Abnormal relationship between medial temporal lobe and subcortical dopamine function in people with an ultra high risk for psychosis. Schizophr Bull (2011) 0.97
The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease. J Neurol Neurosurg Psychiatry (2013) 0.96
Imaging of microglia in patients with neurodegenerative disorders. Front Pharmacol (2012) 0.96